Edwards Lifesciences Corporation
1 Edwards Way
Irvine
California
92614
United States
Tel: 949-250-2500
Fax: 949-250-2525
Website: http://www.edwards.com/
311 articles about Edwards Lifesciences Corporation
-
Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference
2/23/2024
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.
-
Edwards’ EVOQUE Valve Replacement System First Transcatheter Therapy to Earn FDA Approval for Tricuspid Valve
2/2/2024
Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR).
-
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Edwards Lifesciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
-
CLASP IID One-year Data Confirm Safety and Efficacy of Edwards Pascal System for Degenerative Mitral Regurgitation
10/26/2023
Edwards Lifesciences Corporation announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two contemporary mitral transcatheter edge-to-edge repair therapies, as well as one-year results from the CLASP IID registry.
-
TRISCEND II Six-month Data for First 150 Patients Successfully Demonstrate Safety and Efficacy of Edwards Evoque System for Severe Tricuspid Regurgitation
10/26/2023
Edwards Lifesciences Corporation announced successful results from TRISCEND II, a randomized controlled pivotal trial designed to evaluate the safety and effectiveness of the groundbreaking EVOQUE tricuspid valve replacement system with optimal medical therapy compared to OMT alone with 2:1 randomization.
-
EDWARDS EVOQUE TRANSCATHETER TRICUSPID VALVE REPLACEMENT SYSTEM RECEIVES CE MARK
10/19/2023
Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system received CE Mark for the transcatheter treatment of eligible patients with tricuspid regurgitation (TR).
-
EDWARDS LIFESCIENCES TO PRESENT AT THE 2023 WELLS FARGO HEALTHCARE CONFERENCE
8/28/2023
Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.
-
Edwards Announces One-Year Data on Transfemoral Transcatheter Tricuspid Valve Replacement
11/27/2022
Edwards Lifesciences Corporation announced that one-year results on patients treated in the single-arm, prospective, global, multi-center TRISCEND study of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
-
Edwards Announces Six-Month Data Confirming TEER as Safe and Effective for DMR in First Head-to-Head Trial
9/17/2022
Edwards Lifesciences Corporation announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair therapies.
-
EDWARDS LIFESCIENCES TO PRESENT AT THE 40TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
1/5/2022
Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate at the J.P. Morgan Healthcare Conference on Monday, January 10, 2022.
-
Edwards Announces Six-month Data From Transcatheter Tricuspid Replacement Program
11/6/2021
Edwards Lifesciences Corporation announced that results from a clinical trial of the company's EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months.
-
Edwards Lifesciences Reports Second Quarter Results - July 23, 2020
7/23/2020
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, reported financial results for the quarter ended June 30, 2020.
-
Edwards Lifesciences Agrees To Global Transcatheter Litigation Settlement With Abbott
7/13/2020
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has reached an agreement with Abbott to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.
-
Abbott Agrees to Global Transcatheter Litigation Settlement with Edwards Lifesciences
7/13/2020
Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.
-
Edwards SAPIEN 3 Transcatheter Heart Valve Receives Approval In China
6/8/2020
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received Chinese regulatory approval for the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) at high risk for or unable to undergo open-heart surgery.
-
Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
5/18/2020
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation.
-
Edwards Announces Updates From Annual Meeting - May 07, 2020
5/7/2020
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals.
-
Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients
4/27/2020
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients.
-
Edwards Lifesciences Reports First Quarter 2020 Results
4/23/2020
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, reported financial results for the quarter ended March 31, 2020.
-
Edwards Lifesciences To Hold Virtual Annual Meeting Of Stockholders
4/13/2020
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that its Annual Meeting of Stockholders (Annual Meeting) will be held in a virtual meeting webcast format, beginning at 10:00 a.m. PT (1:00 pm ET) on Thursday, May 7, 2020.